Glucotrack, Inc. - 8-K Filing
Glucotrack advances LT-100 development strategy toward single-injection administration following FDA Type C meeting and nonclinical study. (Items: 7.01 Regulation FD Disclosure On July 29, 2026, Glucotrack, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $GCTK